Key clinical point: Upfront treatment with rituximab, lenalidomide, and ibrutinib (RLI) followed by standard chemotherapy, produced high response rates in patients with newly diagnosed non-GCB diffuse large B-cell lymphoma.

Major finding: The overall response rate at the end of therapy was 100%, with a 95% complete response rate and a 5% partial response rate.

Study details: Final phase 2 results from Smart Start, an open-label, single-arm study of 58 patients who received RLI alone in a two-cycle lead in, followed by RLI combined with standard chemotherapy for six cycles.

Disclosures: Dr. Westin reported financial relationships with Curis, Celgene, Janssen, Novartis, Genentech, 47 Inc, Juno, and others.